BioPharma Resources

Drug Trial Radar · NCT01853124

Emergency Department Probiotic Treatment of Pediatric Gastroenteritis

Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Mar 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 886 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

886

Actual

Start

Nov 2013

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Dr. Stephen FreedmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital; The Hospital for Sick Children; Children's Hospital of Eastern Ontario; St. Justine's Hospital; IWK Health Centre; Institut Rosell Lallemand; London Health Sciences Center, Children's Hospital
First posted
May 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 3 months, up to 48 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine for previously healthy children who present to a Canadian Emergency Department (ED) with acute gastroenteritis (infection or irritation of the digestive tract); if compared with placebo, the administration of a probiotic agent (Lacidofil) will result in a significantly lower proportion of children developing moderate to severe disease over the subsequent 2 weeks and will not be associated with a significantly greater occurrence of side effects.

Conditions

  • Gastroenteritis

Interventions

  • PlaceboDrug

    All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.

  • LacidofilDrug

    All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of moderate to severe disease in the 2 weeks after the index visitTime frame: Measured daily for 14 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • IWK Health Centre

    Halifax, Nova Scotia, Canada

  • Children's Hospital, London Health Sciences Center

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Centre Hospitalier Universitaire Sainte Justine

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.